Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).
Comments Off on Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).
April 28, 2026
A phase 2 open-label trial evaluated transdermal CBD for 22q11.2 deletion syndrome in children, demonstrating tolerability with preliminary behavioral improvements. While promising for this rare genetic condition, controlled trials are needed to…
Phase 2 Open-Label INSPIRE Trial on Transdermal CBD Gel in 22q11.2 Deletion Syndrome
Comments Off on Phase 2 Open-Label INSPIRE Trial on Transdermal CBD Gel in 22q11.2 Deletion Syndrome
March 27, 2026
The INSPIRE trial investigates transdermal cannabidiol gel children with 22q11.2 deletion syndrome to assess safety and tolerability. This phase 2 open-label study provides preliminary data on CBD gel use in pediatric neurodevelopmental disorders.…
Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
Comments Off on Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
March 4, 2026
Transdermal cannabidiol gel fragile x syndrome safety data comes from ongoing clinical trials evaluating long-term tolerability in children and adolescents. This synthetic CBD formulation targets behavioral symptoms linked to endocannabinoid…